Stay updated on MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety

Sign up to get notified when there's something new on the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page.
Latest website image capture
Clouds background image

Latest updates to the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Core study content appears unchanged; the screenshots show only superficial UI adjustments with no updates to the Brief Summary, Eligibility Criteria, Interventions, outcomes, or key dates. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-10-27T20:55:29.000Z thumbnail image
  3. Check
    33 days ago
    Change Detected
    Summary
    Update includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.
    Difference
    3%
    Check dated 2025-10-06T07:59:15.000Z thumbnail image
  4. Check
    40 days ago
    Change Detected
    Summary
    The page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.
    Difference
    0.1%
    Check dated 2025-09-29T04:36:29.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Updated page from v3.0.1 to v3.0.2 with no substantive content changes; removal of 'Back to Top' is a minor navigation tweak.
    Difference
    0.2%
    Check dated 2025-09-14T21:55:54.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version of a study on tildrakizumab, with a change in the publication date and version number.
    Difference
    0.4%
    Check dated 2025-09-07T19:09:04.000Z thumbnail image
  7. Check
    69 days ago
    Change Detected
    Summary
    The web page has added significant information regarding the facility name, location, and drug information related to Tildrakizumab, while removing various location details and resources related to psoriasis and other skin diseases.
    Difference
    3%
    Check dated 2025-08-31T12:21:38.000Z thumbnail image

Stay in the know with updates to MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety

Enter your email address, and we'll notify you when there's something new on the MK-3222-010 Clinical Trial: Psoriasis Efficacy & Safety page.